Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

72
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
72
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

106
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
106
Autoimmune Disorders01:29

Autoimmune Disorders

1.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.1K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

108
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
108
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

96
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
96

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High incidence of Y-chromosome mosaicism in male and female individuals with mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy.

Epilepsia·2026
Same author

Significance of critical life events for quality of life in people with epilepsy after presurgical assessment.

Epilepsy & behavior : E&B·2026
Same author

Immune cell profiling reveals expanded stem cell-like memory T cells in anti-GAD65-associated neurological syndromes.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Default Mode Network Resting State Connectivity Derived From Task-Based fMRI: A Validation Study in People With Epilepsy.

Journal of neuroimaging : official journal of the American Society of Neuroimaging·2026
Same author

Dynamic patterns of verbal memory function after an initial decline following temporal lobe resection against epilepsy: Sex-specific differences in the postoperative course.

Epilepsia·2026
Same author

Reduced Hospital Incidence of Autoimmune Encephalitis During the COVID-19 Pandemic.

Neurology(R) neuroimmunology & neuroinflammation·2026

Related Experiment Video

Updated: Nov 20, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.5K

Management of autoimmune encephalitis.

Christian G Bien1,2

  • 1Bielefeld University, Medical School, Department of Epileptology (Krankenhaus Mara), Campus Bielefeld-Bethel, Bielefeld.

Current Opinion in Neurology
|January 19, 2021
PubMed
Summary

The established 1st/2nd line treatment concept for autoimmune encephalitis is supported by new data. Intravenous immunoglobulins are superior to placebo for LGI1-antibody encephalitis, and Rituximab shows promise earlier in treatment. Long-term management requires further research.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.1K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.0K

Related Experiment Videos

Last Updated: Nov 20, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.5K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.1K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.0K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Autoimmune encephalitides are recognized neurological disorders.
  • Their management presents ongoing challenges for neurologists.
  • Current treatment strategies include first-line and second-line interventions.

Purpose of the Study:

  • To evaluate the current relevance of the 1st/2nd line treatment concept for autoimmune encephalitis.
  • To review new data on antibody-defined encephalitis types.
  • To explore strategies for organizing long-term patient management.

Main Methods:

  • Review of recent clinical data and randomized controlled trials.
  • Analysis of treatment outcomes for immunological interventions.
  • Assessment of current practices in long-term care.

Main Results:

  • A randomized controlled trial confirmed the efficacy of intravenous immunoglobulins (IVIg) as a first-line treatment for leucine-rich glioma inactivated protein 1 (LGI1)-antibody encephalitis.
  • Rituximab, a second-line agent, is increasingly used effectively across various autoimmune encephalitis types and may be considered earlier.
  • Existing treatment guidelines are largely confirmed, but long-term management strategies need enhancement.

Conclusions:

  • The 1st/2nd line treatment paradigm for autoimmune encephalitis remains valid, with IVIg demonstrating superiority in specific cases.
  • Rituximab's role in autoimmune encephalitis treatment is expanding, potentially moving earlier in the therapeutic cascade.
  • Further research is essential for optimizing long-term management, including rehabilitation and driving eligibility assessments.